Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Legend Biotech USA Inc.
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
December 09, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Tickers
LEGN
Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
November 12, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Tickers
LEGN
Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
November 07, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Tickers
LEGN
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
November 05, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Tickers
LEGN
Legend Biotech Appoints Alan Bash as President of CARVYKTI®
November 04, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Tickers
LEGN
Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
October 24, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Tickers
LEGN
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
October 03, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Tickers
LEGN
CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
September 27, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Tickers
LEGN
Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 20, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Tickers
LEGN
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
August 09, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Tickers
LEGN
Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors
August 08, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Tickers
LEGN
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
July 26, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Tickers
LEGN
Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
July 10, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Tickers
LEGN
Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
July 02, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Tickers
LEGN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.